Study Summary
This trial will evaluate a new oral combination of targeted drugs, called DTRM-555, for patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin's lymphoma.
- Chronic Lymphocytic Leukemia (CLL)
- Non-Hodgkin's Lymphoma
- Follicular Lymphoma
- Richter's Transformation
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: 6, 12 and 24 months
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
Disease-specific cohorts
1 of 1
Experimental Treatment
120 Total Participants · 1 Treatment Group
Primary Treatment: DTRM-555 · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What prior research efforts have been made with respect to DTRM-555?
"Currently, there are 179 experiments being conducted for DTRM-555. 26 of these trials are in the late stages, Phase 3. Although most studies take place in Hamilton, Ontario, 6803 other clinical sites across the world have also taken part in researching this new treatment option." - Anonymous Online Contributor
How many individuals have joined the trial thus far?
"Affirmative. Data from clinicaltrials.gov confirms that this research endeavour, initially posted on April 24th 2020, is actively recruiting volunteers. 120 individuals need to be sourced from 8 separate institutions." - Anonymous Online Contributor
What potential hazards should be taken into account when handling DTRM-555?
"Despite the absence of clinical data backing its efficacy, our team at Power have evaluated DTRM-555 to be moderately safe with a score of 2." - Anonymous Online Contributor
What ailments has DTRM-555 been clinically proven to help mitigate?
"DTRM-555 is a commonly utilized remedy for dealing with kidney transplant rejection. Additionally, this medication may be of benefit to those suffering from waldenstrom macroglobulinemia, lung issues, and advanced carcinoid tumor." - Anonymous Online Contributor
Are recruiting efforts underway to include participants in this trial?
"Affirmative. Clinicaltrials.gov confirms that enrollment for this clinical trial is open, with the original post dating back to April 24th 2020 and last updated on April 28th 2022. The research team is looking for 120 individuals across 8 medical centres." - Anonymous Online Contributor
How many sites are actively engaged in managing this research endeavor?
"This trial is recruiting subjects at institutions such as University of Pennsylvania Abramson Cancer Center in Philadelphia, Duke Cancer Institute in Durham, and Memorial Sloan Kettering Cancer Centre in New York. In addition to these three sites, there are 8 additional locations taking part in the study." - Anonymous Online Contributor